ZN-7035 / Suzhou Zanrong - LARVOL DELTA

A selective BRM (SMARCA2) inhibitor for the treatment of BRG1 (SMARCA4) mutant cancers (AACR 2025) - "ZN-7035 monotherapy demonstrated anti-tumor activity and synergistic tumor growth inhibition in combination with AMG176, a MCL1 inhibitor, in an NCI-H838 xenograft model carrying BRG1 loss-of-function mutation. ZN-7035 is a highly potent, selective, orally available, small-molecule, enzymatic inhibitor of BRM. Preclinical findings highlight that ZN-7035-based combination therapies have the potential to be effective and safe treatments for patients with tumors harboring BRG1 mutations."

Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • KRT80 • SMARCA2 • SMARCA4